ArticleBMC infectious diseases2026
Serum HDAC3 as an early biomarker for prediction and staging of sepsis-associated AKI: prospective cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionTo investigate the early predictive value of serum histone deacetylase 3 (HDAC3) levels for sepsis-associated acute kidney injury (SA-AKI) and evaluate its ability to differentiate between various stages of acute kidney injury (AKI).
methodsA prospective cohort study was conducted among patients with sepsis admitted to the intensive care unit (ICU) of Yancheng First People’s Hospital between January 2025 and October 2025. All participants met the Sepsis-3 diagnostic criteria and had no AKI at ICU admission. Patients were stratified according to the development of AKI within seven days after diagnosis, and AKI severity was staged using KDIGO guidelines. Multivariable logistic regression was used to identify independent risk factors for SA-AKI. Receiver operating characteristic (ROC) curves were generated to assess the predictive performance of HDAC3 and related biomarkers. Subgroup analysis evaluated the discriminatory ability of HDAC3 between mild (KDIGO stage 1) and severe AKI (KDIGO stages 2–3). Kaplan–Meier survival analysis was performed to examine the association between HDAC3 levels and 28-day survival.
resultsA total of 90 patients with sepsis were enrolled, of whom 50 (55.6%) developed AKI within seven days. Patients with SA-AKI exhibited significantly higher SOFA scores, APACHE II scores, PCT, CRP, and serum HDAC3 levels than those without AKI (P < 0.05). Multivariable analysis identified SOFA score, CRP, PCT, and serum HDAC3 as independent risk factors for SA-AKI. ROC analysis showed that HDAC3 achieved an AUC of 0.820 (95% CI: 0.732–0.908), which was higher than those of SOFA, CRP, and PCT. Serum HDAC3 levels showed a significant stepwise increase across KDIGO stages, and stratified analysis demonstrated an AUC of 0.828 (95% CI: 0.694–0.920) for distinguishing mild from severe AKI. Higher HDAC3 levels were also significantly associated with reduced 28-day survival (log-rank P < 0.05).
conclusionElevated serum HDAC3 levels are associated with the development, severity, and prognosis of SA-AKI. While these findings provide supportive evidence for the potential role of HDAC3 in early risk stratification and AKI staging, validation in larger, multi-center cohorts is required to confirm its clinical utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.